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Abstract 
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Alzheimer's disease (AD) is a severe neurodegenerative disorder. There is no disease 
modifying drugs for AD so far, hence increase of number of AD patients due to population aging 
is a global social issue. Neurofibliraly tangles (NFTs) is a major pathological hallmarks of AD 
and mainly composed of tau protein. Since tau has pivotal role in the pathogenesis of AD and 
other tauopathy diseases, it is important to understand the cell biological basis of abnormal 
production and accumulation for the AD drug discovery. For this purpose, I studied about cell 
biological modulation of abnormal production and accumulation of tau. 
 In the first chapter, I describe the tau gene expression modulation through transcription 
factor Sp1. The tau protein is encoded by microtubule-associated protein tau (MAPT) gene and 
Sp1 binds to the promoter region of MAPT gene. As Sp1 is supposed to affect AD pathology via 
regulating tau/MAPT gene expression, targeting Sp1 is attractive strategy to modulating tau gene 
expression. To investigate basic information of Sp1 as a drug target, I prepared a series of Sp1 
mutant proteins and examined DNA recognition properties of Sp1. From the analysis, I found that 
each of three zinc finger motifs had different role in DNA recognition. I also found that the C-
terminal finger induced conformation change in DNA structure of the N-terminal finger binding 
regions, and that the conformation change affected DNA recognition mode of the N-terminal 
finger. These findings are useful for designing tau expression modulator targeting Sp1. 
In the second chapter, I describe a novel glycogen synthase kinase-3 (GSK-3) inhibitor 
that suppresses tau phosphorylation. Tau is hyperphosphorylated mainly by glycogen synthase 
kinase 3 (GSK-3). Accordingly GSK-3 inhibitor is expected to improve AD pathology by 
inhibiting NFT formation. I discovered a potent and selective GSK-3 inhibitor, compound A and 
found that compound A reduced tau phosphorylation in vitro and in vivo. And chronic treatment 
of compound A in human P301L tau expressing mouse (JNPL3 mice, an AD mice model) resulted 
in significant reduction on not only tau phosphorylation but also abnormal tau aggregation.  
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Taken together, I conclude that cell biological modulation of tau gene expression and 
tau phosphorylation is attractive strategy for AD treatment, and tau–targeting approach is 
promising beyond 'Aβ hypothesis' based approach. 
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Aβ  amyloid β 
AD  Alzheimer’s disease 
ATP  adenosine triphosphate 
DNA  deoxyribonucleic acid 
GSK-3  glycogen synthase kinase-3 
MAPT  microtubule associated protein tau 
NFT  neurofibliraly tangle 
Sp1  specificity protein 1 
SEM  standard error of mean 
  
6 
 
 
 
 
 
 
 
 
 
 
 
General Introduction 
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AD is a severe and progressive neurodegenerative disorder with cognitive impairment 
and personality change due to synaptic and neuronal loss. AD is a most common dementia 
accounting for estimated 60 to 80 percent of cases. Worldwide, nearly 44 million people have 
AD or related dementia, and AD is now 4th leading cause of death in the high income countries 
in the world (1). The global cost of AD and dementia is estimated to be $818 billion in 2015 
(1). Increase of number of AD patients due to population aging is a global social issue. Currently, 
there is no disease modifying drugs for AD with limited treatment options of symptomatic relief.   
The two major pathological hallmarks in brains of AD patients are senile plaques 
composed of Aβ peptides and NFTs composed of abnormally hyperphosphorylated tau protein. 
Aβ targeting drug development/therapies have widely been researched and developed for AD 
treatment, and this strategy has strongly supported by the discovery of disease associated 
mutations in Aβ-related genes, such as amyloid precursor protein, Presenilin-1, and Presenilin-
2. Nevertheless, several large clinical trials of Aβ targeting drug candidates for the treatment of 
AD and mild cognitive impairment have failed over the last decade. Recent multicenter 
neuroimaging study results indicated that Aβ pathology (senile plaques) appeared in the very 
early stages of AD pathology development and preceded clinical symptom, suggesting the 
necessity of the very early intervention and prevention for Aβ targeting treatment (2).  
Recent growing number of evidences supports the idea that NFT is a key driver of 
disease progression in AD (3), and people pay much attention to tau targeting strategy for AD 
drug development. Tau is a microtubule associated protein and mostly localized in axons. 
Physiologically, tau has an important role in microtubule assembly and microtubule stability, also 
contributes maintaining normal axonal integrity and neuronal function (4-6). Tau is supposed to 
have other functions, such as cellular signaling, neuronal development, neuroprotection, and 
apoptosis (4-6). In spite of its important roles in cellular processes, several lines of tau knockout 
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mice were reported to be viable and do not display any gross physical or behavioral abnormalities, 
as microtubule associated protein 1A (MAP1A) may compensate for the loss of tau (4). In AD 
and other tauopathy patient brains, such as Pick's disease (PiD) frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), and 
corticobasal degeneration (CBD), abnormally hyperphosphorylated tau accumulate as paired 
helical filaments (PHF) (5). Abnormally hyperphosphorylated tau is dissociated from microtubule, 
leading to neuronal damage with impaired axonal transport (5). Disease associated mutation in 
MAPT gene were reported in frontotemporal lobar degeneration with parkinsonism 17 (FTDP-
17) patients (7).  
Since tau has pivotal role in the pathogenesis of AD and other tauopathy diseases, it is 
necessary to understand the basis of abnormal production and accumulation for the AD drug 
discovery. For this purpose, I studied about cell biological modulation of abnormal production 
and accumulation of tau. In the first chapter, I describe the tau gene expression modulation 
through transcription factor Sp1. Tau is encoded by MAPT gene and Sp1 binds to the promoter 
region of MAPT gene (8). In AD and other tauopathy patient postmortem brains, Sp1 is 
abnormally expressed (9). As Sp1 is supposed to affect AD pathology via regulating tau/MAPT 
gene expression, targeting Sp1 is attractive strategy to modulating tau gene expression. To 
investigate basic information of Sp1 as drug target, I prepared a series of Sp1 mutant proteins and 
examined DNA recognition properties of Sp1. In the second chapter, I describe a novel GSK-3 
inhibitor that suppresses tau phosphorylation. I discovered a potent and selective GSK-3 inhibitor, 
compound A and found that compound A reduced tau phosphorylation in vitro and in vivo. And 
chronic treatment of compound A in human P301L tau expressing mouse (JNPL3 mice, an AD 
mouse model) resulted in significant reduction on not only tau phosphorylation but also abnormal 
tau aggregation.  
9 
 
  
10 
 
 
 
 
 
 
 
 
 
 
 
Part I 
Finger-positional change in three zinc finger protein Sp1 
: influence of terminal finger in DNA recognition. 
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Abstract 
 
The connection of functional modules is effective for the design of DNA binding 
molecules with the desired sequence specificity. C2H2-type zinc finger proteins have a tandemly 
repeated array structure consisting of independent finger modules and are expected to recognize 
any DNA sequences by permutation, multi-connection, and the substitution of various sets of zinc 
fingers. To investigate the effects of the replacement of the terminal finger on the DNA 
recognition by other fingers, I have constructed the three zinc finger peptides with finger 
substitution at the N- or C-terminus, Sp1(zf223), Sp1(zf323), and Sp1(zf321). From the results of 
gel mobility shift assays, each mutant peptide binds preferentially to the target sequence that is 
predicted if the fingers act in a modular fashion. The methylation interference analyses 
demonstrate that in the cases of the N-terminal finger substitution mutants, Sp1(zf223) and 
Sp1(zf323), the N-terminal finger recognizes bases to different extents from that of the wild-type 
peptide, Sp1(zf123). Of special interest is the fact that the N-terminal finger of the C-terminal 
finger substitution mutant, Sp1(zf321), shows a distinct base recognition from those of 
Sp1(zf123) and Sp1(zf323). DNase I footprinting analyses indicate that the C-terminal finger 
(active finger) induces a conformational change in the DNA in the region for the binding of the 
N-terminal finger (passive finger). The present results strongly suggest that the extent of base 
recognition of the N-terminal finger is dominated by the binding of the C-terminal finger. This 
information provides an important clue for the creation of a zinc finger peptide with the desired 
specificity, which is applicable to the design of novel drugs and biological tools. 
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Introduction 
 
The design of DNA targeting proteins with desired functions is one of the most 
significant problems in the post-genome era and may lead to the creation of new drugs and 
biological tools. To achieve this goal, it is necessary to establish the DNA recognition rule by the 
DNA binding molecules with a well-defined modular structure such as the C2H2-type zinc finger 
and pyrrole−imidazole polyamide (10, 11). The C2H2-type zinc finger motif has a tandemly 
repeated structure consisting of independent modules with the consensus sequence:  (Tyr,Phe)-X-
Cys-X2,4-Cys-X3-Phe-X5-Leu-X2-His-X3-5-His-X2-6. Each finger domain is mostly connected 
by a well-conserved linker and has a compact globular ββα structure due to tetrahedral binding of 
a zinc ion with invariant cysteines and histidines. The first crystal structural analysis of the 
Zif268−DNA complex has provided useful information about the DNA recognition by the C2H2-
type zinc finger motif (12, 13). In the complex, each zinc finger makes direct base contacts by 
using amino acids at positions −1, 2, 3, and 6 in the α-helix that recognizes overlapping four-base-
pair subsites mainly on the guanine-rich strands of the binding site. However, two unique features 
opposed to the modularity of the zinc finger have been reported in the DNA recognition by the 
zinc finger protein. One is the unbalanced influence of these fingers on the DNA binding observed 
in the DNA bindings of Zif268 (14), the C-terminal three fingers of TFIIIA (15), and WT1 (16). 
In them, the N-terminal fingers make particularly smaller contributions to the high-affinity DNA 
binding than the other fingers. The other influence is the relative finger position on the DNA 
binding of the finger. The order change of zinc fingers in an array and sequential selection via the 
phage display give rise to the unexpected effects on the DNA base recognition by zinc fingers 
(17, 18).  
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Transcription factor Sp1 is a sequence-specific DNA binding protein derived from the 
HeLa cell (19, 20). Sp1 has three contiguous repeats of a C2H2-type zinc finger motif at the C-
terminus and activates transcription in various viral and cellular genes by binding to the GC box, 
which has the decanucleotide consensus sequence 5'-(G/T)GGGCGG(G/A)(G/A)(C/T)-3' 
(20−24). Together with the crystallographic evidence of the Zif268−DNA complex, some 
previous studies about the Sp1−DNA interaction revealed that the three zinc fingers of Sp1 also 
make a different contribution to GC-box DNA binding (25-28). Namely, the contribution is 
reduced in the order:  C-terminal finger > central finger > N-terminal finger. Moreover, the N-
terminal zinc finger of Sp1 uniquely binds to DNA, whereas the central and C-terminal zinc 
fingers typically bind to DNA (28). The finger does not utilize His(3), but instead utilizes Lys(−1) 
for the recognition of the guanine bases at the center and the 3'-end of the 5'-GGG-3' subsite 
despite prevalent  recognition of guanine at the center of the 5'-GGG-3' subsite by His(3).  
 
In this study, I prepared three mutant zinc finger peptides, Sp1(zf223), Sp1(zf323), and 
Sp1(zf321), and evaluated the effect of the terminal finger on the base recognition of the other 
fingers in the DNA binding of three zinc finger peptide. The wild-type and mutant peptides 
preferably bind to their predicted binding sequences. Methylation interference and DNase I 
footprinting analyses suggest that the different degrees of base recognition of the N-terminal 
finger of the mutant peptides from that of wild type is due to the DNA conformational change 
induced by the binding of the C-terminal finger. 
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Materials and Methods 
 
Materials  
All enzymes were purchased from New England Biolabs (Beverly, MA, USA), except 
for the restriction enzyme AgeI obtained from Nippon Gene (Tokyo, Japan). The synthesized 
oligonucleotides for construction of the genes and substrate DNAs were acquired from Amersham 
Pharmacia Biotech (Piscataway, NJ, USA）. Labeled compound [γ-32P]ATP was supplied by 
DuPont (Wilmington, DE, USA). The plasmid pBS-Sp1-fl was kindly provided by Dr. R. Tjian. 
All other chemicals were of commercial reagent grade.  
 
Preparation of Zinc Finger Peptides from Sp1  
The primary structures of all the zinc finger peptides used in this study are summarized 
in Figure 1A. Sp1(zf123), which is the alias for Sp1(530−623), is coded on plasmid 
pEVSp1(530−623) as previously described (29). For the creation of Sp1(zf223) and Sp1(zf323), 
the finger 2, 3, and 2−3 gene fragments were amplified by PCR with the primer set of 
pEVSp1(530−623) as a template. The amplified single-finger fragments were designed to be 
flanked by the N-terminal region with the BamHI site at the 5'-end and the AgeI site at the 3'-end. 
On the other hand, the double-finger fragments were amplified aite at the 5'- and 3'-ends, 
respectively. The AgeI enzyme site in the linker region encodes amino acids Thr-Gly, part of the 
linker peptide between fingers 1 and 2. By digesting one set of single- and double-finger 
fragments with enzymes and ligating them into the similarly digested pEV3b, I constructed the 
plasmids pEVSp1(zf223) and pEVSp1(zf323), which code Sp1(zf223) and Sp1(zf323), 
respectively. The plasmid pEVSp1(zf321) coding Sp1(zf321) was created by ligating the N-
terminal double-finger gene fragment from pEVSp1(zf323) and the finger 1 gene fragment from 
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pEVSp1(530−623) in the same manner as described above. All sequences were confirmed by the 
BcaBEST Dideoxy Sequencing Kit (Takara Shuzo, Kyoto, Japan). These zinc finger peptides 
were overexpressed in Escherichia coli strain BL21(DE3)pLysS and purified as previously 
described (28), except for the use of 1 mM dithiothreitol as the reductant.  
 
Preparation of Substrate DNA Fragments  
The substrate oligonucleotides contain the target binding site predicted from the binding 
mode of the transcription factor Sp1:  GC(123), 5'-GGG GCG GGGCC-3'; GC(223), 5'-GGG 
GCG GCGGC-3'; GC(323), 5'-GGG GCG GGGGC-3'; GC(321)-1, 5'-GGGC GCG GGGGC-3'; 
and GC(321)-2, 5'-GGGCC GCG GGGGC-3'. The synthesized oligonucleotides were annealed 
and inserted in pBluescript II SK+ (Stratagene, La Jolla, CA, USA). The HindIII−XbaI fragment 
was cut out and labeled at the 5’-end by 32P for the experiments.  
 
Circular Dichroism (CD) Measurements  
The CD spectra of the wild-type and mutant zinc finger peptides of Sp1 were recorded 
on a Jasco J-720 spectropolarimeter in 10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM 
dithiothreitol, and 5 μM zinc finger peptide at 20°C.  
 
Gel Mobility Shift Assays  
Gel mobility shift assays were carried out under the following conditions. Each reaction 
mixture contained 10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM dithiothreitol, 10 μM ZnCl2, 
25 ng/μL poly(dI-dC), 0.05% Nonidet P-40, 5% glycerol, 40 mg/μL BSA, the 32P-end-labeled 
substrate DNA fragment (∼50 pM), and 0−4 μM zinc finger peptide. After incubation at 20°C for 
30 min, the sample was run on a 12% polyacrylamide gel with Tris−borate buffer at 20°C. The 
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bands were visualized by autoradiography and quantified with NIH image software (version 1.62). 
The dissociation constants (Kd) of the Sp1 peptide−DNA fragment complexes were estimated 
based on a previously reported procedure (28).  
 
Methylation Interference Analyses  
Methylation interference assays were investigated as previously described (27, 29). The 
binding reaction mixture contained 10 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM dithiothreitol, 
10 μM ZnCl2, 20 or 25 ng/μL competitor DNA, 0.05% Nonidet P-40, 5% glycerol, the 32P-end-
labeled methylated DNA fragment (∼40 nM, 400 Kcpm), and 10−500 nM zinc finger peptides. 
As competitor DNAs, 20 ng/μL sonicated calf thymus DNA and 25 ng/μL poly(dI-dC) were used 
for the experiments shown in Figures 3 and 4, respectively. To examine both the strong and weak 
base contacts in the methylation interference experiment, I selected the experimental conditions 
such that the peptide/DNA molar ratio in the binding reaction was about 10−20% bound. 
Densitometric measurements were obtained with NIH image software (version 1.62). The extent 
of interference was estimated as previously described (28).  
 
DNase I Footprinting Analyses  
DNase I footprinting experiments were performed according to the method of Brenowitz 
et al. (30). The binding reaction mixture contained 20 mM Tris-HCl (pH 8.0), 15 mM NaCl, 5 
mM CaCl2, 10 mM MgCl2, 20 ng/μL sonicated calf thymus DNA, the 5‘-end-labeled substrate 
DNA fragment (∼8 nM, 20 000 cpm), and 0−10 μM peptide. After incubation at 20°C for 30 min, 
the sample was digested with DNase I (0.75 milliunit/μL) at 20°C for 2 min. The reaction was 
stopped by the addition of 20 μL of DNase I stop solution (0.1 M EDTA and 0.6 M sodium 
acetate) and 100 μL of ethanol. After ethanol precipitation, the cleavage products were analyzed 
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on a 10% polyacrylamide/7 M urea sequencing gel. The bands were visualized by 
autoradiography.  
 
18 
 
Results 
 
Design of Mutant Zinc Finger Peptides, Sp1(zf223), Sp1(zf323), and Sp1(zf321) and Their 
Predicted Binding Sequences  
To study the effect of the terminal finger of the three finger peptide on DNA binding of 
the peptide, I prepared three mutant zinc finger peptides, Sp1(zf223), Sp1(zf323), and Sp1(zf321) 
(Figure 1A, left panel). Sp1(zf223) and Sp1(zf323), in which the N-terminal finger 1 of 
Sp1(zf123) is replaced with fingers 2 and 3, respectively, are  the mutants for the evaluation of 
the N-terminal finger properties. On the other hand, the effect of replacing the C-terminal finger 
on the DNA binding mode is estimated by the preparation of a mutant peptide, Sp1(zf321), which 
has three zinc fingers arrayed inversely in comparison with Sp1(zf123). Previous study 
demonstrated that the finger 3-deleted mutant, Sp1(zf12), formed no stable complex with the GC-
box DNA under my experimental conditions because of the small contribution of finger 1 to the 
DNA binding (28). Therefore, I did not design Sp1(zf121) but Sp1(zf321), considering the 
deficiency of the DNA binding ability of Sp1(zf121). 
The predicted binding sequences, which are designed from the putative DNA binding 
mode of Sp1 (Figure 1B; 28), are shown in Figure 1A (right panel). The wild-type GC-box 
sequence, GC(123), is derived from the mouse dihydrofolate reductase promoter (I and III) (18, 
19). GC(223) and GC(323) are the target sequences for Sp1(zf223) and Sp1(zf323), respectively. 
From the results of the previous interference experiment for Sp1(zf123), finger 1A of Sp1(zf123) 
recognizes uniquely the five-base-pair subsite (28). On the contrary, the zinc finger proteins such 
as Zif268 exhibit the typical recognition of the three-base-pair subsite by each finger domain (12). 
To clarify whether the base recognition mode of finger 1C of Sp1(zf321) is typical or unique, I 
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prepared two sequences, GC(321)-1 and -2, in addition to GC(321)-0 which is identical to the 
target sequence for Sp1(zf323).  
 
Examination of the Folding Property of Wild-Type and Mutant Zinc Finger Peptides of Sp1  
To examine the change in the folding property by finger substitution, I analyzed the 
secondary structures of the peptides based on measurements of the CD spectra. Figure 2 shows 
the CD measurement results for the peptides at 20°C. The spectrum for Sp1(zf123) was similar 
to those of the single- and three-finger peptides of Sp1 previously described (31-33). Negative 
Cotton effects in the far-UV region with a minimum at 206 nm and a shoulder around 222 nm 
suggest that Sp1 (zf123) has an ordered secondary structure. The spectrum for Sp1(zf321) was 
quite similar to that of Sp1(zf123). On the other hand, Sp1(zf223) and Sp1(zf323) exhibited 
spectra somewhat different from those of Sp1(zf123) and Sp1(zf321). As for the ellipticities at 
206 nm, the values of Sp1(zf123) and Sp1(zf321) ([θ]206 = −11 936, −10 984, respectively) were 
distinct from those of Sp1(zf223) and Sp1(zf323) ([θ]206 = −14 205, −14 673, respectively). This 
is probably due to the difference in the composition of the fingers. These results indicate that the 
conformation of the finger domain in each peptide is not identical but comparable with that of 
each other. I obtained the same results at 4°C (data not shown). 
 
Evaluation of the Binding Affinity of Mutant Zinc Finger Peptides to Wild-Type and 
Mutant GC Boxes  
By using gel mobility shift assays, I obtained the dissociation constants (Kd) of these 
peptide−DNA complexes as summarized in Table 1. Sp1(zf123) binds to GC(123) with a 5.3 nM 
dissociation constant, which is comparable to the previously reported value, whereas GC(223) 
and GC(323) dissociation constants were 57 and 22 nM, respectively. The Kd values for the 
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Sp1(zf223)−GC(123), −GC(223), and −GC(323) complexes were 41, 3.9, and 21 nM, 
respectively. On the other hand, the Kd values for Sp1(zf323) binding to GC(123), GC(223), and 
GC(323) were 24, 60, and 6.6 nM, respectively. These results suggest that each mutant mentioned 
above binds to the predicted binding sequence with the highest affinity under my experimental 
condition. 
On the contrary, Sp1(zf321) binds to the wild-type and mutant GC boxes with a 70−250-
fold lower affinity than the other peptides. The dissociation constants of Sp1(zf321) for GC(123), 
GC(223), and GC(323) are 994, 286, and 314 nM, respectively, indicating that GC(223) and 
GC(323) are preferable to GC(123) for the binding of Sp1(zf321) to DNA. All peptides used in 
this study showed no effective binding to GC(321)-2. GC(321)-1 was bound only by Sp1(zf123) 
and Sp1(zf323) with 714 and 512 nM dissociation constants, respectively.  
 
Specific Base Recognition Mode of Mutant Zinc Finger Peptides Revealed by Methylation 
Interference Analysis  
Figure 3A shows the methylation interference patterns of Sp1(zf123), Sp1(zf223), and 
Sp1(zf323) for GC(123), GC(223), and GC(323), respectively. The extent of the interference 
based on a densitometric analysis is shown by histograms (Figure 3B). The interference patterns 
at subsites I and II were the same among these peptides. In contrast, distinct interference patterns 
were observed at subsite III. Namely, the recognition of G7 in Sp1(zf223) and Sp1(zf323) was 5-
fold stronger than in Sp1(zf123), and the recognitions of G10 in Sp1(zf223) and Sp1(zf323) and 
G11' in Sp1(zf223) were almost lost. In Figure 3C, I compared the extent of the interference of 
fingers 2 and 3 on the basis of the difference in the relative position, suggesting that the difference 
has a significant effect on the base recognition of the cognate fingers. 
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   Figure 4 shows the results of the methylation interference assay for Sp1(zf321). From the 
results of the evaluation of Kd, Sp1(zf321) binds to GC(223) and GC(323) with a higher affinity 
than the other DNAs. Therefore, I carried out an experiment using such peptide−DNA 
combinations in which Sp1(zf323) was employed as the control. Panels A and B depict the 
electrophoretic results and the densitometric analysis for Sp1(zf321), respectively. There is no 
obvious difference in the extent of interference between the Sp1(zf321)− and 
Sp1(zf323)−GC(223) complexes. In the binding to GC(323), Sp1(zf321) shows an interference 
pattern distinct from that of Sp1(zf323). The bases at subsite III were not strongly recognized by 
Sp1(zf321), as is distinct from the case with Sp1(zf323). 
 
Analysis of Conformational Changes of DNA Induced by Binding of Mutant Zinc Finger 
Peptides  
Figure 5 shows the DNase I footprinting patterns of Sp1(zf123), Sp1(zf223), Sp1(zf323), 
and Sp1(zf321) for their high-affinity binding sequences. All mutant peptides protected the wild-
type or mutant GC box from cleavage by DNase I in both strands. Hypersensitive cleavage was 
observed at the 5'-AA-3' step outside the GC box in the guanine-rich strand (G-strand), whereas 
no cleavage induction by protein binding was detected in the cytosine-rich strand (C-strand). In 
addition, hypersensitive cleavage was also induced in the G-strand by the binding of Sp1(zf321) 
between G8 and G9 in the GC box. The same footprinting patterns were also obtained in the case 
of the wild-type and mutant Sp1 peptide−GC(123) complexes (data not shown).  
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Discussion 
 
Effects of Replacement of Finger 1 in Sp1(zf123) on DNA Binding Affinity and Specificity 
Based on previous mutational analyses of Sp1(zf123) and the GC boxes (28), the 
relative contribution of the three fingers of Sp1(zf123) to the DNA binding affinity was shown to 
be reduced in the order of finger 3 > finger 2 > finger 1. It is expected that the replacement of 
finger 1 with finger 2 or 3 in Sp1(zf123) leads to an increase in the DNA binding affinity of 
Sp1(zf123). The results presented here show that both Sp1(zf223) and Sp1(zf323) preferentially 
bind to their predicted binding sequences with a dissociation constant comparable to that of 
Sp1(zf123). In contrast, the deletion of finger 1 from Sp1(zf123) results in an 89-fold reduction 
in the binding affinity to GC(123) (28). Together with this evidence, the results indicate that these 
mutants evidently make use of all three fingers in DNA binding and that the N-terminal fingers, 
fingers 2A and 3A of Sp1(zf223) and Sp1(zf323), respectively, make an equivalent contribution 
to the DNA binding of finger 1A of Sp1(zf123).  
The extent of base recognition of Sp1(zf223) and Sp1(zf323) appears to be distinct in 
part from that of Sp1(zf123). From the results of the methylation interference analyses, the two 
fingers at positions B and C of the mutant peptides maintain the same base recognition mode as 
that of Sp1(zf123). With respect to their fingers at position A, the strong interference patterns of 
Sp1(zf223) and Sp1(zf323) at G7 in the G-strand suggest that they recognize bases at subsite I 
like fingers 1 and 2 of Zif268, respectively, in contrast to finger 1A of Sp1(zf123), which 
recognizes G8 and G9 by Lys(−1) and exhibits a weak interference pattern at G7. The direct 
comparison of the extent of base recognition by them with that in their native positions 
demonstrates the difference in the extent of recognition (Figure 3C). In Sp1(zf323), G7 is 
recognized 1.5-fold stronger than G1. The extent of the recognition is also stronger than that of 
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G7 in Sp1(zf123) by a factor of 3.7. In the DNA binding of the zinc finger protein, the helicity of 
the recognition helix increases by the C-cap formation in the linkers connecting adjacent fingers 
at the C-terminal side (34). The increase in the recognition of G7 in the Sp1(zf323)−GC(323) 
complex may be elucidated by the increment of helicity induced by new C-cap formation in finger 
3A of Sp1(zf323). However, the mutation of Ala(6) to arginine in finger 1A of Sp1(zf123), which 
was carried out for the increase in the recognition of G7 in the Sp1(zf123)−GC(123) complex 
considering the typical base recognition mode of the zinc finger peptide, had no drastic effect on 
the recognition of G7 in GC(123) despite the plausibility of the original C-cap formation in finger 
1A of Sp1(zf123) (35). This evidence suggests that the extent of recognition of G7 by the finger 
at position A of these Sp1 peptides is undetermined only by the C-cap formation in the finger.  
In contrast, the recognition of G9 by finger 2A of Sp1(zf223) is 5-fold weaker than the 
recognition of G6 by finger 2B. A rationale for the disruption of the base recognition by a terminal 
zinc finger is reported as an end effect (14). In this theory, the base recognition by the amino acids 
such as Arg(18) and Arg(80), which are situated at positions −1 and 6 in the α-helices of fingers 
1 and 3 of Zif268, respectively, is less sensitive to the mutation to glycine than the other critical 
amino acid residues. This is not applicable to my system for the following reason:  no decrease in 
the base recognition by finger 3A of Sp1(zf323) was observed, whereas a similar decrease was 
detected in the Sp1(zf223)−GC(223) complex.  
 
Effects of Replacement of Finger 3 in Sp1(zf123) on DNA Binding Affinity and Specificity  
Previous report revealed that finger 1A of Sp1(zf123) recognizes the five-base-pair 
subsite (28). On the basis of several X-ray crystallographic analyses (12, 13, 36-39), fingers 1C, 
2B, and 3A of Sp1(zf321) are expected to bind to subsites I, II, and III, respectively, and the 
predicted binding sequence for finger 1C is not the five- but the three-base-pair site, 5‘-NGG-3‘, 
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in the G-strand. The actual DNA binding affinity of Sp1(zf321) for various GC boxes estimated 
by the calculation of the Kd values suggests that a pertinent interaction between finger 1C and 
subsite III does not occur in GC(321)-1 or -2, but in GC(123), GC(223), and GC(323). The 
inability of Sp1(zf321) binding to GC(321)-1 and -2 also demonstrates that Sp1(zf321) did not 
bind to the DNA by the N-terminal two-finger domain in contrast to the ability of the two-finger 
peptide, Sp1(zf23), to bind to GC(123) (28). This evidence indicates that the constitution and 
order of the finger is important for DNA binding of the zinc finger protein with a high affinity 
and specificity despite the sufficiency of the two-finger domain for DNA binding. For the DNA 
binding of the two-finger peptide composed of fingers 2 and 3, fingers 2 and 3 need to be aligned 
in the direction from amino- to carboxyl-termini.  
   As evidenced by the comparison of the results of the methylation interference analyses and 
estimation of the Kd values of Sp1(zf321) with those of other mutants, the base recognition mode 
of finger 1C of Sp1(zf321) is distinct from that of finger 1A of Sp1(zf123). Finger 1C of 
Sp1(zf321) appears to have the typical base recognition mode of the zinc finger protein. That is 
to say, Lys(−1) and His(3) recognize G3 and G2 in subsite I. G1 might be recognized by Arg(5). 
The base recognition by Arg(5) was also discovered in the GLI−DNA complex, in which Arg(5) 
in finger 5 recognizes guanine at position 4' (36). In addition, it is of special interest that the base 
recognition mode of finger 3A of Sp1(zf321) is clearly different from that of finger 3A of 
Sp1(zf323). Replacement of finger 3C by finger 1 in Sp1(zf323) induced a 15-fold reduction in 
the extent of recognition of G8 by finger 3A. As mentioned earlier, the extent of base recognition 
by the finger at position A is distinct from that of the finger at the native position in the cases of 
Sp1(zf223) and Sp1(zf323). Therefore, the zinc fingers at positions A and C are passive and active 
fingers, respectively.  
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Effects of Conformational Change of DNA Induced by the Binding of Active Finger on DNA 
Binding of Passive Finger  
Several conformational changes of DNA induced by the binding of the zinc finger 
protein, such as bending (29, 37, 39, 40), local distortion (28), and unwinding (41), have been 
reported. DNA bending is induced by the bindings of Tramtrack, Sp1, and TFIIIA. Based on my 
CD data for the wild-type and mutant peptides, no drastic conformational change in each finger 
domain appears to occur, suggesting that the conformational change of DNA has effects on the 
DNA binding of the peptides. For the investigation of the existence of DNA bending, DNase I 
footprinting analyses are available, since hypersensitive cleavage of DNA by DNase I induced by 
the binding of protein is generally attributed to a conformational change in the DNA, in particular 
bending (42). In fact, such a hypersensitive cleavage has also been observed in the 3‘-region 
outside the GC-box in the G-strand for the binding of the zinc finger of Sp1 to the GC-box DNA, 
and this is consistent with the evidence of DNA bending by circular permutation analyses (28, 29, 
40). Therefore, I applied DNase I footprinting analyses to the examination of the DNA bending 
by the Sp1 mutants. My footprinting results clearly show that Sp1(zf321) produces bending of 
the GC-box DNA at subsite III. The hypersensitive cleavage at the G8−G9 step does not occur in 
the binding of Sp1(zf323), indicating that finger substitution at position C in Sp1(zf323) induces 
a structural change. The other conformational change of DNA by Sp1 binding is local distortion 
of the GC-box DNA in the 3'-region of the G-strand revealed by previous footprinting analyses 
(27). In the binding of Sp1(zf123) to GC(123), finger 1A recognizes the bases of the region in a 
unique manner. Together with the result that finger 1 shows the typical base recognition mode by 
transferring from positions A to C, it is suggested that the conformational distortion has an effect 
on the base recognition mode and/or extent of the  zinc finger at position A. Moreover, the 
distortion is induced by the binding of the C-terminal two fingers of Sp1(zf123) (Sogo et al., 
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unpublished data), indicating that Sp1(zf223) and Sp1(zf323) also cause a distortion in subsite III 
by the C-terminal two fingers upon binding to DNA and fingers 2A and 3A may show different 
extents of base recognition than that in the native positions. In the mechanism described above, 
the N- and C-terminal fingers in the three-finger-peptide are passive and active fingers for base 
recognition of DNA, respectively.  
 
In this paper, I report “the active and passive fingers mechanism in DNA recognition by three-
zinc-finger peptide” which is based on the conformational change in DNA induced by the C-
terminal finger. This concept is not always applicable to the DNA binding of other zinc finger 
proteins. In fact, all zinc fingers equivalently bind to DNA without any induction of a 
conformational change in DNA during the DNA binding of Zif268 and YY1 (12, 13, 38). In the 
N-terminal six zinc fingers of the TFIIIA−DNA complex, however, DNA is bent in the binding 
regions of fingers 1 and 2 (39). Recently, it was reported that the three-zinc-finger domain binds 
to DNA as one unit during the DNA binding of the zinc finger protein by multiconnection of 
identical zinc fingers (43). Therefore, in the design of zinc finger proteins with a novel sequence 
preference, selection of the third finger (passive finger) at the N-terminus of a two-finger domain 
containing an active finger is desirable. Thus far, the DNA recognition code of the zinc finger has 
been analyzed by a phage display method (44-47). While most of sequences can be recognized 
by zinc finger proteins, unrecognized sequences remain. I may overcome this problem by 
considering the presented information in the design of novel zinc finger peptides. Additionally, 
such peptides give promise of the application of the zinc finger peptide to the design of novel 
drugs and biological tools. 
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Tables and Figures 
 
Table 1:  Dissociation Constants (Kd) for Spl(zf123), Sp1(223), Sp1(zf323), and Sp1(zf321) 
Binding to Wild-Type (GC) and Mutant GC Boxes. a, Apparent dissociation constants were 
determined by titration using a gel mobility shift assay as described under Materials and Methods. 
Values are averages of three or more independent determinations with standard deviations. B, The 
nomenclature is described in the text (see Figure 1). c, ND, not determined. 
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  Kd (nM)a  
binding siteb  Sp1(zf123)  Sp1(zf223)  Sp1(zf323)  Sp1(zf321)   
GC(123) 5.3 ± 0.4   41 ± 2.2   24 ± 1.1   994 ± 45   
GC(223) 57 ± 2.6   3.9 ± 0.2   60 ± 2.3   286 ± 29   
GC(323) 22 ± 1.6   21 ± 1.0   6.6 ± 0.2   314 ± 15   
GC(321)-1   714 ± 74  >4000   512 ± 57   >4000   
GC(321)-2   >4000   >4000   >4000   NDc 
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Figure 1. (A) Primary structures of wild-type and mutant zinc finger peptides of Sp1 (left) and 
their predicted binding sequences (right). The designation of each zinc finger is shown by the 
original name (fingers 1−3) with an alphabetical letter indicating the absolute position (positions 
A−C). Substituted or inserted nucleotides in the mutated GC-box sequences are depicted in 
boldface type. The base numbers in the wild-type and mutant GC boxes are also shown. (B) Mode 
of putative interaction of Sp1 with GC-box DNA. Amino acid residues at the N-terminus of the 
α-helix in each finger are depicted by their one-letter codes with the number of helical positions 
below. Solid arrows show the amino acid−base contacts assumed by the DNA binding mode of 
Zif268, and dotted arrows depict the contacts indicated by previous report. 
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Figure 2. CD spectra of wild-type and mutant zinc finger peptides of Sp1 at 20°C. 
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Figure 3. (A) Methylation interference analyses for Sp1(zf123), Sp1(zf223), and Sp1(zf323) 
binding to GC(123), GC(223), and GC(323), respectively. The left (lanes 1−9) and right (lanes 
10−18) panels show the results for the G- and C-strands, respectively. Lanes 1, 4, and 7 and lanes 
10, 13, and 16 contain G+A and C+T of the Maxam−Gilbert sequencing reactions, respectively. 
The remaining lanes represent free (F) and peptide-bound (B) DNA samples. In these experiments, 
calf thymus DNA was used as a competitor (see Materials and Methods for details). (B) A 
histogram showing the extent of methylation interference by Sp1(zf123), Sp1(zf223), and 
Sp1(zf323). Three or more autoradiograms of the gels were scanned with a densitometer, and the 
average extent of interference was calculated as the ratio of the cutting probabilities for the two 
bands (B/F). (C) Direct comparisons of the extent of interference between finger 2B of Sp1(zf123) 
and finger 2A of Sp1(zf223) (left) and between finger 3C of Sp1(zf123) and finger 3A of 
Sp1(zf323) (right). 
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Figure 4. (A) Methylation interference analyses for Sp1(zf323) and Sp1(zf321) binding to 
GC(223) and GC(323). The left and right panels show the results for GC(223) and GC(323), 
respectively. Lanes 3−10 represent free (F) and bound (B) DNA samples. Lanes 2 and 11 contain 
G+A and C+T of the Maxam−Gilbert sequencing reactions, respectively. Lanes 1 and 12 show 
intact DNA. In these experiments, poly(dI-dC) was used as a competitor (see Materials and 
Methods for details). (B) Histograms showing the extent of methylation interference by 
Sp1(zf323) and Sp1(zf321) for GC(223) (left) and GC(323) (right). Two or more autoradiograms 
of the gels were scanned with a densitometer, and the average extent of interference was 
calculated as the ratio of the cutting probabilities for the two bands (B/F). 
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Figure 5. DNaseI footprinting analyses for Sp1(zf123), Sp1(zf223), Sp1(zf323), and Sp1(zf321) 
binding to their high-affinity binding sequence. Panels A and B show the results for the G- and 
C-strands, respectively. The asterisks represent the enhance sites of cleavage. Lanes 1, 6, 11, 16, 
and 21 in panel A, G+A (Maxam−Gilbert reaction products); lanes 1, 6, 11, 16, and 21 in panel 
B, C+T (Maxam−Gilbert reaction products). Peptide concentrations and the combinations of 
peptide and substrate DNA are noted in the figure 
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Supplementary Figure 1. DNaseI footprinting analyses for Sp1(zf123), Sp1(zf223), Sp1(zf323), 
and Sp1(zf321) bindings to GC(123). Left and right panels show the results for the G- and C-
strands, respectively. The asterisks represent enhance site of cleavage. Lanes 2, 15, and 16 in left 
panel, G+A (Maxam-Gilbert reaction products); Lanes 2, 15, and 16 in right panel, C+T (Maxam-
Gilbert reaction products). Peptide concentrations are noted in the figure. 
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Part II 
Efficacy of a Novel, Orally Active GSK-3 Inhibitor 6-Methyl-N-[3-[[3-(1-
methylethoxy)propyl]carbamoyl] -1H-pyrazol-4-yl]pyridine-3-carboxamide 
 in Tau Transgenic Mice 
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Abstract 
 
Neurofibrillary tangles (NFTs) composed of hyperphosphorylated and aggregated tau 
are common pathological characteristics in Alzheimer’s disease (AD) and other tauopathies. 
Aberrant tau phosphorylation is an early and pivotal event in the pathogenesis of tauopathies, and 
since GSK-3 is a key factor implicated in aberrant tau phosphorylation, GSK-3 inhibition is 
expected to suppress tauopathy disease progression. In the present study, I report the efficacy of 
a newly discovered small molecule GSK-3 inhibitor, 6-methyl-N-[3-[[3-(1-
methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide (compound A), to 
inhibit tau phosphorylation and to reduce the amount of pathological aggregated tau in JNPL3 
mice that overexpress a mutant form of human tau. Compound A is a highly potent and selective 
inhibitor of GSK-3 with an IC50 of 2 nM, with at least 230-fold lower potency against 27 other 
kinases. Oral administration of compound A resulted in a significant reduction of tau 
phosphorylation at several GSK-3 directed sites. Furthermore, chronic oral administration of 
compound A markedly reduced aggregated tau in old JNPL3 mice. These results suggest that a 
novel, orally active GSK-3 inhibitor, compound A, has potency in the prevention of tau pathology. 
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Introduction 
 
Neurofibrillary tangles (NFTs) composed of hyperphosphorylated and aggregated tau 
are common pathological characteristics in several neurodegenerative diseases, such as 
Alzheimer’s disease (AD), frontotemporal dementia with parkinsonism linked to chromosome 17 
(FTDP-17), Pick’s disease, progressive supranuclear palsy, and corticobasal degeneration that are 
collectively called tauopathies (48, 49). In AD, the temporal and spatial distribution of NFTs 
correlates well with clinical disease severity (50, 51). Tau is a microtubule-associated protein, 
and its normal physiological function is to bind and stabilize microtubules (52). Aberrant 
phosphorylated tau loses its ability to bind to and stabilize microtubules, leading to disruption of 
the microtubule assembly and deficits in axonal transport (53-56). Considering recent studies 
reporting age-dependent synaptic deficits, hippocampal degeneration and memory impairment in 
transgenic mice overexpressing mutant forms of tau (57, 58), strategies targeting tau pathology 
are attractive for the treatment of AD and other tauopathies. 
Previous studies have demonstrated that tau is a substrate of various kinases, such as 
cyclin dependent kinase 5 (CDK5), mitogen-activated protein kinase (MAPK) and glycogen 
synthase kinase-3β (GSK-3β) (59-65). Among these kinases, GSK-3β has been reported to be the 
predominant tau kinase involved in most of the hyperphosphorylated serine/threonine residues in 
PHF-tau both in vitro and in vivo (60). Overexpression of GSK-3β in mammalian cells and 
transgenic mice resulted in tau hyperphosphorylation, microtubule destabilization, and 
pathological PHF formation (66-68). In addition, a conditional GSK-3β overexpressing transgenic 
mouse exhibited some phenotypes such as neuronal death in the hippocampus and cognitive 
deficits (67, 68). Furthermore, active GSK-3β is localized to pretangle neurons, dystrophic 
neurites and NFTs in AD brains, and a spatial and temporal pattern of increased active GSK-3β 
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expression coinciding with the progression of NFTs and neurodegeneration has been observed 
(69, 70). These observations support a major contribution of GSK-3β in the progression of AD 
and other tauopathies. Several groups have investigated different classes of small molecule GSK-
3 inhibitors (71-74), however, there are only a few reports that describe the efficacy of small 
molecule GSK-3 inhibitors on in vivo tau pathology (75, 76). 
In the present study, I report the efficacy of a newly discovered small molecule GSK-3 
inhibitor 6-methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-
carboxamide (compound A) on tau pathology. Compound A is a highly potent and selective GSK-
3 inhibitor with oral activity and has a significant inhibitory effect on in vivo tau phosphorylation. 
In addition, chronic administration of compound A resulted in a marked reduction of aggregated 
tau in old JNPL3 mice that overexpress a mutant form of human tau (77).  
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Materials and Methods 
 
Antibodies 
The following antibodies were used for immunoblotting at appropriate concentrations 
as recommended by the manufacturers. Mouse monoclonal antibodies recognizing phospho-
specific epitopes on tau, AT8 for Ser202/Thr205, AT180 for Thr231, and AT270 for Thr181, and 
human total tau, HT-7, were purchased from Innogenetics (Ghent, Belgium). Rabbit polyclonal 
antibodies recognizing phospho-specific epitopes on tau, Thr205, Ser262, Ser396, and Ser422 
were purchased from Biosource International (Camarillo, CA, USA). Rabbit polyclonal antibody 
recognizing total tau, Tau Ab-3, was purchased from Lab Vision Corporation (Fremont, CA, 
USA). Mouse monoclonal antibody recognizing β-actin was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  
 
Animals 
Male C57BL/6Njcl mice, age 8 weeks, (Clea Japan, Tokyo, Japan) were used for the 
cold water stress model. Homozygous JNPL3Hlmc mice (Taconic Farms, Germantown, NY, 
USA) were also used in this report. JNPL3 are transgenic mice that overexpress human 4R0N tau 
with the FTDP-17 (P301L) mutation (77). All animals were housed in groups and were allowed 
free access to food and water. All animals used in this study were cared for in accordance with 
the Principles and Guidelines on Animal Experimentation of the Pharmaceutical Research 
Division of Takeda Pharmaceutical Company Ltd. 
 
Cold Water Stress (CWS) 
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CWS (78, 79) was given between 13:00 and 18:00. Thirty min after oral administration 
of compound A, mice were immersed up to the neck in cold water (1-2°C) for 4 min and then 
were returned to individual cages. Mice were sacrificed by decapitation 30 min after the CWS, 
the brains were immediately removed, and the hippocampi were dissected. 
 
Drugs and Drug Administration 
6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-
carboxamide (compound A) was synthesized in the Pharmaceutical Research Division of Takeda 
Pharmaceutical Company Ltd. (Osaka, Japan). In the case of the CWS model, compound A was 
suspended in 0.5% methylcellulose and was administered orally in a volume of 10 ml/kg of body 
weight 30 min before the CWS. 
In the JNPL3 study, JNPL3 mice were divided into two matching groups. In the study 
with female JNPL3 mice, age 5.5 months, compound A was suspended in 0.5% methylcellulose 
at 10 mg/ml and was administered to mice twice daily in a volume of 10 ml/kg of body weight by 
oral gavage for 1 month. Mice were sacrificed 30 min after the final treatment by decapitation 
and the brains were immediately removed. One brain hemisphere was frozen in powdered dry ice, 
and the other half was immediately homogenized in ice-cold radio-immunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl (pH 7.6), 5 mM ethylenediamine tetra acetic acid (EDTA), 1 
mM ethylene glycol tetraacetic acid (EGTA), 30 mM NaF, 5 mM sodium diphosphate, 2 μM 
pepstatin A, 100 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 μM microcystin LR, 40 
μM leupeptin, 100 μM 4-(2-aminoethyl)benzenesulfonyl fluoride (ABSF), 2 mM sodium 
orthovanadate, 1 μM MG115). In the study with male JNPL3 mice, age 12.5 months, mice were 
singly housed two weeks before starting treatment, and their basal food intake was measured. 
Subsequently, mice were treated by feeding with chow containing 200 mg of compound A per kg 
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chow (0.02%) for 1 month. In this dosing paradigm, 26 mg/kg/day of compound A were 
administered to the mice. Mice were sacrificed by decapitation, and tissues were analyzed as 
described below. 
 
Preparation of Protein Extract 
Tissues were immediately homogenized in ice-cold RIPA buffer and centrifuged at 
20,000 ×g for 10 min at 4°C. The supernatants were transferred to fresh tubes and were used as 
the soluble fraction. For analysis of aggregated tau from JNPL3 mice, sarkosyl extraction was 
performed (80, 81). The pellets were rehomogenized with 0.5 M NaCl containing 10% sucrose 
and incubated with a final volume of 1% sarkosyl for 1 hour at 37°C. After centrifugation at 
256,000 ×g for 15 min, the pellets were resuspended by ultrasonication in phosphate buffered 
saline, and this suspension was used as the sarkosyl insoluble fraction.  
Total protein lysate of AD patient hippocampus was purchased from BioChain Institute, 
Inc. (Hayward, CA, USA). After centrifugation at 20,000 ×g for 10 min at 4°C, the pellet was 
used for sarkosyl extraction as described above. 
RAB-RIPA-Formic Acid extraction was also performed (82-84). The tissue was 
homogenized in ice-cold high-salt RAB buffer [0.1 M morpholineethanesulfonic acid (MES), 1 
mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M NaF, 100 M ABSF and protease inhibitors 
(Complete Mini, Roche Applied Science, Mannheim, Germany), pH 7.0], and the sample was 
centrifuged at 50,000 ×g for 20 min at 4°C. The supernatant was boiled for 5 min and then 
centrifuged at 10,000 ×g for 20 min at 4°C. The resulting supernatant contains the soluble tau 
fraction (RAB fraction). To remove myelin and associated lipids, the RAB insoluble pellets were 
reextracted with 1 M sucrose/RAB buffer and centrifuged at 100,000 x g for 30 min at 4°C. The 
pellets were suspended in RIPA buffer and centrifuged as above and the supernatants were 
49 
 
collected (RIPA fraction). Finally, the RIPA-insoluble pellets were reextracted with 70% formic 
acid (FA). Protein concentrations were determined using BCA protein assay reagents (PIERCE, 
Rockford, IL, USA).  
 
SDS-PAGE and Western Blotting  
Samples containing 3-10 μg of proteins were separated on a 10% SDS-polyacrylamide 
gel and were transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was 
washed once with 0.1% Tween-20 containing Tris-buffered saline (TBS-T) for 15 min before 
treatment with Block-Ace (DS Pharma Biomedical, Tokyo, Japan) for 45 min and then was 
probed with primary antibody in TBS-T containing 3% bovine serum albumin (BSA). The 
membrane was washed 3 times with TBS-T and then incubated with the anti-mouse or anti-rabbit 
IgG horseradish peroxidase-linked species-specific F(ab’)2 fragment (GE Healthcare, Piscataway, 
NJ, USA) in TBS-T for 1 hour. After washing 3 times with TBS-T, the blot was developed with 
ImmunoStar Reagents (Wako Pure Chemical Ind., Osaka, Japan). The images obtained with a 
CCD camera (LAS-1000plus Luminescent Image Analyzer, Fuji Film, Tokyo, Japan) were 
quantified by densitometry (Image Gauge Ver. 3.46, Fuji Film).  
 
Preparation and Treatment of Rat Primary Cortical Neuron 
Rat primary neuronal cells were prepared from E17 rat fetus (Japan SLC, Hamamatsu, 
Japan). The cells were suspended in NeuroBasal medium (Invitrogen Life Technologies, Carlsbad, 
CA) supplemented with B27 supplement (Invitrogen Life Technologies), 0.5 mM glutamine and 
penicillin-streptomycin. The cells were cultured on poly-L-lysine coated plates (Sumitomo 
Bakelite, Akita, Japan) under a 5% CO2 atmosphere at 37°C. The cells were then treated with 
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compound A in 0.1% dimethylsulfoxide (DMSO), and cultured for 2 hours. Following 2 hours of 
drug treatment, the culture media was removed and the cells were extracted into RIPA buffer. 
 
Immunohistochemistry 
After dissection, each brain was frozen in powdered dry ice. Frozen brains were 
sectioned at 20 μm thickness using a Leica CM-1850 cryomicrotome (Leica Microsystems 
Nussloch GmbH, Nussloch, Germany) and were mounted onto silane-coated slides. After fixation 
with Mildform 10 N (Wako Pure Chemical Ind.), slides were washed with TBS containing 1 mM 
CaCl2 (TBS-Ca), treated with 0.1% Triton X-100 containing TBS-Ca for 30 min, and then treated 
with 0.6% hydrogen peroxide in methanol for 30 min. After blocking with Block-Ace containing 
3% fetal bovine serum, slides were probed with primary antibodies followed with horseradish 
peroxidase (HRP)-coupled secondary antibodies, detected by 3,3’-diaminobenzidine 
tetrahydrochloride (DAKO Cytomation, Glostrup, Denmark), and counterstained with 
hematoxylin. The images were captured using a Nikon Eclipse E800M microscope (Nikon, Tokyo, 
Japan) and a Nikon Dxm1200 camera (Nikon). 
 
GSK-3 or CDK5 Kinase Assay 
The human GSK-3α was purchased from Millipore Corp. (Bedford, MA), which was 
expressed as an N-terminal 6xHis-tagged protein using a baculovirus expression system. Human 
GSK-3β was expressed as an N-terminal FLAG-tagged protein using a baculovirus expression 
system (Takeda Pharmaceutical Company Ltd., Osaka, Japan). Human p35/cyclin dependent 
kinase 5 (CDK5) was purchased from Millipore Corp., which was expressed as an N-terminal 
GST fusion protein using a baculovirus expression system. The kinase assay was performed in a 
reaction mixture that contained 25 mM HEPES, pH 7.5, 10 mM magnesium acetate, 1 mM 
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dithiothreitol, and 0.01% BSA and serially diluted test compounds. The assay was done in a 96-
well plate assay format. The final amount of enzyme and substrate were optimized for each 
kinase: GSK-3α (40 ng/well of enzyme, 400 ng/well of GSK-3 substrate peptide (Millipore 
Corp.)); GSK-3β (40 ng/well of enzyme, 100 ng/well of GSK-3β substrate peptide (Millipore 
Corp.)); CDK5 (20 ng/well of enzyme, 1 ng/well of CDK5 substrate peptide (Calbiochem, La 
Jolla, CA)). 
All the kinase reactions were started by addition of the ATP solution (final 500 nM), 
and were incubated for 45 min at room temperature for GSK-3α or 90 min at 37 °C for GSK-3β 
or for 45 min at room temperature for CDK5. The reactions were terminated by the Kinase-Glo 
reagent containing EDTA (50 μl/well, Promega Corp., Madison, WI). Ten minutes after addition 
of the Kinase-Glo reagent, luminescence was measured on a Wallac ARVO 1420 (PerkinElmer, 
Shelton, CT). The reaction window was calculated from the difference of the average signals 
obtained from the control (5% DMSO) and the background wells. The compound inhibition was 
expressed as the inhibitor concentration that produced 50% inhibition (IC50) of the activity 
without compound. The IC50 values were obtained by linear regression analysis with a GraphPad 
Prism (version 3.02 for Windows, GraphPad Software, Inc., San Diego, CA). The best fit lines 
were obtained by analyzing the logistic fitting equation. 
 
Serine/threonine Kinase Profiling by IC50 Measurement 
Assays for 14 serine/threonine kinases using radio labeled [γ-33P] ATP (GE Healthcare, 
Piscataway, NJ) were performed in 96 well plates. Mitogen-activated protein kinase p38 alpha 
(p38α), extracellular signal-regulated kinase 1 (ERK1), protein kinase C theta (PKCθ), Jun N-
terminal kinase 1 (JNK1) and B-raf were expressed as N-terminal FLAG tagged proteins using a 
baculovirus expression system. I kappa B kinase β (IKKβ) and MEK kinase 1 (MEKK1) were 
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expressed as C-terminal FLAG tagged proteins using a baculovirus expression system. Aurora-B 
was expressed as N-terminal 6xHis tagged protein using a baculovirus expression system. MEK1 
was expressed as N-terminal GST fusion protein using a freestyle293 (Invitrogen Life 
Technologies) expression system. Cyclic AMP-dependent protein kinase (PKA) was expressed 
using an Escherichia coli (E.coli) expression system. Casein kinase 1 delta (CK1δ) was expressed 
as an N-terminal GST fusion protein using an E.coli expression system. Checkpoint kinase 1 
(CHK1) was expressed as an N-terminal GST fusion protein using a baculovirus expression 
system. CDK1/CycB and CDK2/CycA were expressed as C-terminal 6xHis-tagged CDK1 or 
CDK2, and N-terminal GST-tagged Cyclin B or Cyclin A proteins using a baculovirus expression 
system. 
The reaction conditions were optimized for each kinase: p38α (100 ng/well of enzyme, 
1 μg/well of myelin basic protein (MBP) (Wako pure chemical Ind.), 0.1 μCi/well of [γ-33P] ATP, 
60 min reaction at 30°C); ERK1 (100 ng/well of enzyme, 2 μg/well of MBP, 0.1 μCi/well of [γ-
33P] ATP, 60 min reaction at 30°C); MEKK1 (25 ng/well of enzyme, 1 μg/well of MBP, 0.1 
μCi/well of [γ-33P] ATP, 60 min reaction at 30°C); PKCθ (25 ng/well of enzyme, 2 μg/well of 
MBP, 0.1 μCi/well of [γ-33P] ATP, 60 min reaction at 30°C); JNK1 (10 ng/well of enzyme, 1 
μg/well of c-Jun, 0.1 μCi/well of [γ-33P] ATP, 60 min reaction at 30°C); IKKβ (20 ng/well of 
enzyme, 1 μg/well of IκBα, 0.1 μCi/well of [γ-33P] ATP, reaction at room temperature); B-raf (25 
ng/well of enzyme, 1 μg/well of GST-MEK1(K96R), 0.1 μCi/well of [γ-33P] ATP, 20 min reaction 
at room temperature); MEK1 (100 ng/well of enzyme, 0.3 μg/well of GST-ERK1 (K71A) 0.2 
μCi/well of [γ-33P] ATP, 20 min reaction at room temperature); Aurora-B (50 ng/well of enzyme, 
30 μM of Aurora substrate peptide, 0.2 μCi/well of [γ-33P] ATP, 60 min reaction at room 
temperature); PKA (3 nM of enzyme, 1 μM of PKA substrate peptide (Millipore, Corp.), 0.2 
μCi/well of [γ-33P] ATP, 10 min reaction at room temperature); CDK1/CycB (4.2 ng/well of 
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enzyme, 1 μg/well of Histone H1 (Calbiochem), 0.2 μCi/well of [γ-33P] ATP, 20 min reaction at 
room temperature); CDK2/CycA (1.8 mUnits/well of enzyme, 1 μg/well of Histone H1, 0.2 
μCi/well of [γ-33P] ATP, 20 min reaction at room temperature); CK1δ (120 ng/well of enzyme, 
2.4 μM of CK1tide (Millipore Corp.), 0.2 μCi/well of [γ-33P] ATP, 20 min reaction at room 
temperature); CHK1 (30 ng/well of enzyme, 25 μM of CHKtide (Millipore Corp.), 0.2 μCi/well 
of [γ-33P] ATP, 10 min reaction at room temperature). 
Except for the PKCθ, enzyme reactions were performed in 25 mM HEPES, pH 7.5, 
with 10 mM magnesium acetate, 1 mM dithiothreitol and 500 nM ATP containing an optimized 
concentration of enzyme, substrate and radiolabeled ATP as described above in a total volume of 
50 µl. For PKCθ, enzyme reactions were performed in 25 mM HEPES, pH 7.5, with 10 mM 
magnesium acetate, 1 mM dithiothreitol, and lipid activator (Millipore Corp.). 
Prior to the kinase reaction, compound and enzyme were incubated for 5 min at the 
reaction temperature as described above. The kinase reactions were initiated by the addition of 
ATP. After the reaction period as described above, the reactions were terminated by the addition 
of 10% trichloroacetic acid (final concentration). The [γ-33P]-phosphorylated proteins were 
filtered in a Harvest Plate (Millipore Corp.) with a Cell Harvester (PerkinElmer) and then free [γ-
33P] ATP was washed out with 3% phosphoric acid. The plates were dried, followed by the 
addition of 40 µl of MicroScint0 (PerkinElmer). The radioactivity was counted by a TopCount 
scintillation counter (PerkinElmer). 
 
Tyrosine Kinase Profiling by IC50 Measurement  
The cytoplasmic domain of vascular endothelial growth factor receptor 2 (VEGFR2) 
was expressed as an N-terminal FLAG-tagged protein using the baculovirus expression system. 
The cytoplasmic domains of v-erb-a erythroblastic leukemia viral oncogene homolog 2 (ERBB2) 
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and epidermal growth factor receptor (EGFR) were expressed as N-terminal peptide 
(DYKDDDD)-tagged proteins using a baculovirus expression system. These expressed kinase 
proteins were purified using an anti-FLAG M2 affinity gel (Sigma-Aldrich). Fibroblast growth 
factor receptor 3 (FGFR3), platelet-derived growth factor receptor alpha (PDGFRα), PDGFRβ, 
TIE2, c-Met, c-Kit, Src, insulin receptor (IR), and lymphocyte-specific protein tyrosine kinase 
(Lck) were purchased from Millipore Corp.  
Assays for 10 tyrosine kinases, except ERBB2 and EGFR, using anti-phosphotyrosine 
antibodies were performed in 384 well plates using the Alphascreen® system (PerkinElmer) at 
room temperature. Enzyme reactions were performed in 50 mM Tris-HCl, pH 7.5, containing 5 
mM MnCl2, 5 mM MgCl2, 0.01% Tween-20, 2 mM dithiothreitol, 0.1 μg/ml biotinylated poly-
GluTyr (4:1) and optimized concentrations of enzyme and ATP as described below.  
Prior to the kinase reaction, compound and enzyme were incubated for 5 min at room 
temperature. The reactions were initiated by the addition of ATP. After the reaction period 
(described below), the reactions were stopped by the addition of 25 μl of 100 mM EDTA, 10 
μg/ml Alphascreen streptavidine donor beads and 10 μg/ml acceptor beads (described below) in 
62.5 mM HEPES, pH 7.4, 250 mM NaCl, and 0.1% BSA. The plates were incubated in the dark 
for more than 12 hours and then read by an EnVision 2102 Multilabel Reader (PerkinElmer). The 
well containing substrate and enzyme without compound was used as a total reaction control. The 
reaction conditions for these 10 kinases were optimized for each kinase: VEGFR2 (19 ng/ml of 
enzyme, 10 μM ATP, 10 min reaction, PY-100 conjugated acceptor beads (PY-100)); FGFR3 (20 
ng/ml of enzyme, 20 μM ATP, 10 min reaction, PY-100); PDGFRα (50 ng/ml of enzyme, 10 μM 
ATP, 30 min reaction, PT66 conjugated acceptor beads (PT66)); PDGFRβ (50 ng/ml of enzyme, 
20 μM ATP, 60 min reaction, PT66); TIE2 (20 ng/ml of enzyme, 2 μM ATP, 10 min reaction, 
PT66); c-Met (1 ng/ml of enzyme, 2 μM ATP, 10 min reaction, PT66); c-Kit (10 ng/ml of enzyme, 
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20 μM ATP, 20 min reaction, PT66); Src (0.33 ng/ml of enzyme, 2 μM ATP, 10 min reaction, 
PY-100); IR (100 ng/ml of enzyme, 10 μM ATP, 60 min reaction, PT66); Lck (100 ng/ml of 
enzyme, 2 μM ATP, 30 min reaction, PY-100). 
Assays for ERBB2 and EGFR kinases using radiolabeled [γ-32P] ATP (GE Healthcare) 
were performed in 96 well plates. ERBB2 and EGFR kinase reactions were performed in 50 mM 
Tris-HCl, pH 7.5, 5 mM MnCl2, 0.01% Tween-20 and 2 mM dithiothreitol containing 0.9 µCi of 
[γ-32P] ATP per reaction, 50 µM ATP, 5 µg/ml poly-Glu-Tyr (4:1), 0.1% DMSO and 0.25 µg/ml 
of ERBB2 or EGFR cytoplasmic domains in a total volume of 50 µl. Prior to the kinase reaction, 
compound and enzyme were incubated for 5 min at room temperature. The kinase reactions were 
initiated by the addition of ATP. After the kinase reacted for 10 minutes (ERBB2) and 5 minutes 
(EGFR) at room temperature, the reactions were terminated by the addition of 10% trichloroacetic 
acid (final concentration). The [γ-32P]-phosphorylated proteins were filtered in a Harvest plate 
(Millipore Corp.) with a Cell harvester (PerkinElmer) and were washed free of [γ-32P] ATP with 
3% phosphoric acid. The plate was dried, followed by the addition of 25 µl of MicroScint0 
(PerkinElmer). The radioactivity was counted by a TopCount scintillation counter (PerkinElmer). 
 
Plasma and Brain Exposure Measurement 
Compound A was administered to non-fasted C57BL/6N mice (male, 8 weeks old, n= 
3) orally (10 mg/kg, 0.5% methylcellulose suspension). At 30, 60 and 120 minutes after oral 
administration, blood and brain (hippocampus, cerebral cortex, and celleberum) samples were 
collected. The blood samples were centrifuged to obtain the plasma fraction. The brain samples 
were homogenized in saline to obtain the brain homogenate. The plasma and brain homogenate 
samples were deproteinized with acetonitrile containing an internal standard. After centrifugation, 
the supernatants were decanted into microplates, and were diluted with 0.01 mol/L ammonium 
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formate and acetonitrile (7/3, v/v) containing 0.2% formic acid. After another centrifugation, the 
supernatants were injected into a LC/MS/MS system to measure the compound concentrations. 
 
Statistical Analyses 
Statistical analysis was performed by statistical analysis software (SAS pre-clinical 
package, version 5.0; SAS Institute, Inc., Cary, NC). Values were expressed as mean ± S.E.M. 
and statistically analyzed by using unpaired Student’s t-test or one-tailed Williams’ test, which is 
a suitable test for a dose dependent study.  
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Results 
 
Novel GSK-3 Inhibitor compound A 
In the search for novel GSK-3 inhibitors, compound A was selected for further study 
on the basis of its enzyme inhibition, pharmacokinetics, and tau phosphorylation assay results in 
primary neuronal cells. The chemical structure of compound A is shown in Figure 6. Compound 
A inhibited GSK-3α with an IC50 value of 2.3 nM and GSK-3β with an IC50 value of 2.0 nM in 
the presence of 500 nM ATP. In order to assess the selectivity of compound A, I measured its 
inhibitory potency against a number of serine/threonine and tyrosine kinases (Table 2). This 
compound had no inhibitory effect on 23 kinases including extracellular signal-regulated kinase 
1 (ERK1), cAMP-dependent protein kinase (PKA) and p38α, and only weak inhibition was 
detected against CDK1/CycB, CDK2/CycA, CDK5 and Jun N-terminal kinase (JNK) 1 with IC50 
values of 2, 0.46, 5, and 5.8 μM, respectively. Compound A markedly inhibited tau 
phosphorylation in rat primary neuronal cells, indicating it has good cell membrane permeability. 
Compound A treatment resulted in a reduction of tau phosphorylation at GSK-3 directed sites as 
detected by AT8 (pSer202/pThr205), AT180 (pThr231), AT270 (pThr181), pThr205 and pSer396 
antibodies in a concentration dependent manner with IC50 values of 1.9, 0.44, 24, 0.25, and 5.2 
μM, respectively (Figure 7). Compound A did not reduce tau phosphorylation at GSK-3 non-
directed pSer262 and pSer422 sites and also did not affect the amount of total tau. These results 
suggest that compound A reduces tau phosphorylation in primary neuronal cells thorough GSK-
3 inhibition. 
 
Effect of Compound A on Tau Phosphorylation in a Cold Water Stress Model 
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Some previous reports have indicated that cold water stress (CWS) transiently induces 
in vivo tau hyperphosphorylation, and a single intraperitoneal administration of the GSK-3 
inhibitor lithium chloride (LiCl) inhibited CWS-induced tau hyperphosphorylation (78, 79). I 
used the CWS model to evaluate the in vivo efficacy of the novel GSK-3 inhibitor compound A 
on tau phosphorylation. The concentrations of Compound A measured in plasma, hippocampus, 
cerebral cortex, and cerebellum after 30, 60, and 120 min are summarized in Table 3. Compound 
A was suspended in 0.5% methylcellulose and was administered orally 30 min before CWS at a 
dose of 1-10 mg/kg. As indicated in Figure 8, compound A significantly inhibited tau 
phosphorylation in a dose dependent manner as detected by the pThr205 antibody. 10 mg/kg of 
compound A reduced tau phosphorylation to the level of the CWS non-treated control group. 
Compound A displayed a highly potent inhibition of in vivo tau phosphorylation in the CWS 
model. 
 
Evaluation of Compound A Efficacy in JNPL3 Mice Expressing Human Tau 
I then investigated the ability of compound A to inhibit tau hyperphosphorylation and 
tau aggregation in a JNPL3 mouse model. JNPL3 mice are well characterized transgenic mice 
that express human 4R0N tau with a FTDP-17 (P301L) mutation. Their phenotype mimics 
features of human tauopathies (77); in particular, the levels of sarkosyl insoluble tau in JNPL3 
mice increase in an age dependent manner and co-migrate with insoluble tau from AD and FTDP-
17 brains. Thus, JNPL3 mice are a useful model to evaluate tau targeting agents for the treatment 
of AD or other tauopathies. 
Initially, I treated homozygous female JNPL3 mice at age 5.5 months with compound 
A for 1 month. It was previously reported that a significant amount of sarkosyl insoluble tau was 
detected in brain tissue from JNPL3 mice of this approximate age (77). From the results of the 
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CWS model and the pharmacokinetic profile, I determined a dose for compound A of 10 mg/kg 
twice daily by oral gavage. There was no significant reduction of body weight in the compound 
A treated group as compared with the vehicle treated group (data not shown). Compound A 
treatment resulted in a significant reduction of tau phosphorylation at GSK-3 directed sites as 
detected by pThr205, pSer396, AT8, AT180 and AT270 antibodies in the soluble tau fraction 
(Figure 9A, B). Consistent with the results in primary neurons, the most striking reduction was 
seen at the AT180 (pThr231) sites. As for GSK-3 non-directed pSer262 and pSer422 sites, 
compound A did not significantly reduce tau phosphorylation. I then investigated the effect of 
compound A on aggregated, sarkosyl insoluble tau that was biochemically similar to NFTs. 
Compound A treatment resulted in a 49%, 66%, and 58% reduction of sarkosyl insoluble tau 
detected by total tau, pThr205, and HT7 antibodies, respectively (Figure 9C, D); however, these 
reductions were not significant due to the variability in the amounts of sarkosyl insoluble tau in 
JNPL3 mice. I also conducted immunohistochemical analyses. Phosphorylated tau signals 
detected by a pThr205 antibody were markedly decreased by compound A treatment especially 
at CA1, CA3, and dentate gyrus regions (Figure 10A-H). Human tau specific signals detected by 
HT-7 were also reduced in compound A treated mice brains (Figure 10I-P). Since compound A 
did not affect the amounts of the soluble fractions of total tau and aggregated tau was mainly 
composed of transgenic human tau in JNPL3 mice brains (77), these results indicate that 
compound A treated mice had reduced levels of aggregated tau. 
I next examined the ability of compound A to prevent later stage tau pathology by using 
much older JNPL3 mice (12.5 months old). As determined from my preliminary study that the 
amounts of tau protein in aged male JNPL3 mice varied less than in female mice, I used male 
mice for this experiment. In this experiment, 26 mg/kg/day of compound A was administered to 
mice for 1 month by feeding, with no significant changes observed in food intake and body weight 
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as compared to the control group (Supplemental Figure 2). Immunohistochemical analyses 
revealed that pThr205 and HT-7 signals were strikingly diminished by compound A treatment 
(Figure 11). Compound A treatment also showed a significant reduction of sarkosyl insoluble tau 
(total tau, -60%; pThr205, -61%; HT7, -66%) (Figure 12). I have also determined a significant 
effect of compound A on insoluble tau extracted by another procedure (RAB-RIPA-FA extraction, 
Supplemental Figure 3). Thus, chronic oral treatment of the novel GSK-3 inhibitor compound A 
led to a robust reduction of pathological aggregated tau at a later stage of tau pathology. 
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Discussion 
 
NFTs composed of hyperphosphorylated, aggregated tau are a common hallmark of 
tauopathies, such as Alzheimer’s disease and FTDP-17. Since abnormal tau phosphorylation is 
considered to be an early and pivotal event in the pathogenesis of tauopathies and GSK-3 is a key 
factor in aberrant tau phosphorylation, GSK-3 inhibition is expected to mitigate disease 
progression in tauopathies. Indeed, some groups have already demonstrated the ameliorating 
effects of lithium, used as a treatment of mood disorder for many years, on tauopathies (75, 85-
87). Several classes of small molecule GSK-3 inhibitors have already been developed (71-74); 
however, there are few reports describing the in vivo efficacy of these compounds on tau 
pathology (75, 76, 88). In the current report, I investigate the in vitro/in vivo efficacy of a recently 
discovered, novel GSK-3 inhibitor, compound A, to inhibit tau phosphorylation and aggregated 
tau. 
Compound A is selective for GSK-3 with an IC50 of 2 nM and 230-fold lower potencies 
for 27 other kinases. Compound A has been found to be one of the most potent and selective 
GSK-3 inhibitors as compared to previously reported compounds (71, 77, 88) and shows 
inhibitory effects on tau phosphorylation at GSK-3 directed sites in primary neuronal cells and 
mouse brain tissue. Yoshida et al. reported that intraperitoneal administration of 300 mg/kg of 
LiCl led to a partial suppression of CWS induced tau phosphorylation (79), while in the current 
study I found that 10 mg/kg of compound A completely inhibited CWS induced tau 
phosphorylation. As compound A is an orally active GSK-3 inhibitor with high potency and 
selectivity, it should be a useful tool in examining the possibility of selective GSK-3 inhibition as 
a tauopathy treatment. 
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In the soluble tau fraction from JNPL3 mice, compound A reduced phosphorylation 
among all examined phosphorylation sites most robustly at the Thr231 residue. This result 
indicates that the Thr231 site is mainly phosphorylated by GSK-3 in vivo, and it has been reported 
that in AD brains pThr231 signals were detected in the earliest stages of tau pathology preceding 
NFT formation (89, 90). Accordingly, GSK-3 may play an important role in the onset of 
tauopathies by phosphorylating the Thr231 residue. Since GSK-3 has been shown to 
phosphorylate tau at most sites in PHF-tau, GSK-3 inhibition would be anticipated to reduce tau 
phosphorylation at multiple sites. My results indicate that GSK-3 inhibition by compound A led 
to a significant reduction of tau phosphorylation at several GSK-3 directed sites. Meanwhile, 
Steinhilb et al. reported that phosphorylation of a group of serine-proline/threonine-proline sites 
plays a fundamental role in tau-mediated toxicity in a tau transgenic Drosophila model (91). They 
also revealed that no single phosphorylation residue plays a dominant role in tau-mediated toxicity, 
which suggests that multiple sites work together to promote neurodegeneration (92). These data 
indicate that GSK-3 inhibitors have the potential of delaying the onset and halting the progression 
of tau pathologies by inhibiting tau phosphorylation at multiple sites. 
Chronic administration of compound A significantly reduced sarkosyl-insoluble tau in 
old homozygous JNPL3 mice (12.5 months old). In contrast, chronic administration of lithium 
failed to reduce sarkosyl-insoluble tau in old heterozygous JNPL3 mice (12 months old) (75) or 
pre-formed NFTs in FTDP-17 tau / GSK-3β transgenic mice (87). Considering the in vitro activity 
and the results from the CWS model (79), I speculate that these results are mainly due to the weak 
inhibitory activity of lithium against GSK-3. To my knowledge, this report is the first to show 
that administration of a GSK-3 inhibitor reduced sarkosyl-insoluble tau in old tau transgenic mice, 
which suggests that chronic inhibition of GSK-3 by a highly potent and selective inhibitor has the 
possibility of preventing NFT formation even in a later stage of tau pathology. Although the role 
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of NFTs in disease progression has not yet been fully elucidated, NFTs are thought to play a 
crucial role in the disease progression of AD and other tauopathies based on studies with 
postmortem brains of AD patients that demonstrate the number of NFTs correlates well with the 
degree of cognitive impairment (50, 51). It is plausible that intracellularly accumulated NFTs of 
relatively large size directly exert toxic effects on cells and contribute to tauopathy disease 
progression. Thus, the efficacy of compound A toward reducing sarkosyl-insoluble tau in old 
JNPL3 mice is a significant result. 
In summary, I have demonstrated the efficacy of the novel, potent, selective, orally 
active GSK-3 inhibitor compound A for significantly reducing tau phosphorylation and 
aggregated tau. Chronic administration of compound A led to a significant reduction of 
aggregated tau in old JNPL3 mice brains. Further research on compound A and related 
compounds as a tauopathy treatment will be needed to clarify their efficacy on neurodegeneration 
and cognitive impairment especially in the later stages of disease. 
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Tables and Figures 
 
Table 2. Kinase selectivity of compound A 
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Ser/Thr 
Kinase 
IC50 (M) of 
compound A 
Tyr Kinase 
IC50 (M) of 
compound A 
GSK-3α 2.3E-09 EGFR >1.0E-05 
GSK-3β 2.0E-09 ERBB2 >1.0E-05 
CDK5 5.0E-06 Src >1.0E-05 
AuroraB >1.0E-05 Lck >1.0E-05 
MEK1 >1.0E-05 IR >1.0E-05 
B-raf >1.0E-05 TIE2 >1.0E-05 
ERK1 >1.0E-05 c-Kit >1.0E-05 
PKA >1.0E-05 c-Met >1.0E-05 
CDK1/CycB 2.0E-06 VEGFR2 >1.0E-05 
CDK2/CycA 4.6E-07 FGFR3 >1.0E-05 
CHK1 >1.0E-05 PDGFRα >1.0E-05 
p38α >1.0E-05 PDGFRβ >1.0E-05 
JNK1 5.8E-06   
IKKβ >1.0E-05   
MEKK1 >1.0E-05   
PKCθ >1.0E-05   
CK1δ >1.0E-05   
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Table 3. Concentration of compound A in mouse plasma, hippocampus, cerebral cortex, and 
cerebellum after oral administraton at a dose of 10 mg/kg. Determination of concentration of 
compound A was performed as described in the Experimental Procedure. 
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Time after 
administration (hr) 
Concentration of Compound A (μM, n = 3, mean ±SEM) 
Plasma 
 Hippocampus Cerebral cortex Cerebellum 
0.5 1.45 ± 0.06 0.66 ± 0.13 0.48 ± 0.04 0.39 ± 0.03 
1 0.20 ± 0.01 0.19 ± 0.02 0.16 ± 0.02 0.14 ± 0.01 
2 0.04 ± 0.02 0.08 ± 0.02 0.05 ± 0.01 0.04 ± 0.02 
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Figure 6. Chemical structure of novel GSK-3 inhibitor compound A. 
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Figure 7. Compound A reduced tau phosphorylation in rat primary cortical neurons in a 
concentration dependent manner. Rat primary cortical neurons at DIV4 were treated with 
compound A at 0.03-30 μM for 2 hours. Cells were extracted and analyzed by immunoblot with 
phosphorylated tau antibodies: AT8, AT180 and AT270 and total tau antibody. 
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Figure 8. Effect of compound A on cold water stress (CWS) induced tau phosphorylation. 
Compound A was administered orally at a dose of 1-10 mg/kg 30 min before the CWS. 0.5% 
methylcellulose was administered to mice as a vehicle treated control. Mice were subjected to 
CWS for 4 min and sacrificed 30 min after CWS. A, Proteins from CWS treated mice 
hippocampus were separated by SDS-PAGE and detected by pThr205 and total tau antibodies. B, 
Immunoblot bands were quantified by densitometry. Data represent means ± S.E.M. of 5 animals 
and are expressed as phospho-tau normalized to total tau. Significance is defined as *** p ≤ 0.001 
(t-test) in comparison to the non-stressed group and as + p ≤ 0.025 (Williams’ test) in comparison 
to the vehicle administered group. 
 
  
73 
 
 
 
 
 
  
74 
 
Figure 9. Effects of compound A on tau phosphorylation and aggregated tau in JNPL3 mice brain. 
Compound A was administered at a dose of 10 mg/kg twice daily by oral gavage for 1 month to 
female JNPL3 mice (5.5 months old). A, Proteins from the RIPA soluble fractions of JNPL3 mice 
hemispheres were separated by SDS-PAGE and detected by pThr205, pSer262, pSer396, pSer422, 
AT8, AT180, AT270 and total tau antibodies. B, Immunoblot bands were quantified by 
densitometry. Data represent means ± S.E.M. of 10 animals and are expressed as phospho-tau 
normalized to total tau. Significance is defined as * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 (t-
test) in comparison to the vehicle administered group. C, Proteins from sarkosyl insoluble 
fractions were separated by SDS-PAGE and detected by total tau, pThr205, and HT7 antibodies. 
D, Immunoblot bands were quantified by densitometry. Data represent means ± S.E.M. of 10 
animals. 
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Figure 10. Immunohistochemical analysis of compound A treated JNPL3 mice brains. Compound 
A was administered at a dose of 10 mg/kg twice daily by oral gavage for 1 month to female JNPL3 
mice (5.5 months old). PThr205 and HT7 immunostaining were performed in vehicle treated mice 
(pThr205; A-D, HT7; I-L) and compound A treated mice (pThr205; E-H, HT7; M-P), in the 
hippocampus (A, E, I, M) (magnification, 40x), the CA1 (B, F, J, N) (magnification, 600x), the 
CA3 (C, G, K, O) (magnification, 600x), or the dentate gyrus regions (D, H, L, P) (magnification, 
600x). Hematoxylin was used for counterstaining. 
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Figure 11. Immunohistochemical analysis of compound A treated JNPL3 mice brains. Compound 
A was administered at a dose of 26 mg/kg/day by feeding for 1 month to male JNPL3 mice (12.5 
months old). PThr205 and HT7 immunostaining were performed in vehicle treated mice 
(pThr205; A-D, HT7; I-L) and compound A treated mice (pThr205; E-H, HT7; M-P), in the 
hippocampus (A, E, I, M) (magnification, 40x), the CA1 (B, F, J, N) (magnification, 600x), the 
CA3 (C, G, K, O) (magnification, 600x), or the dentate gyrus regions (D, H, L, P) (magnification, 
600x). Hematoxylin was used for counterstaining. 
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Figure 12. Effects of compound A on insoluble/aggregated tau in JNPL3 mouse brain. Male 
JNPL3 mice, age 12.5 months, were treated by feeding with chow containing 200 mg compound 
A per kg chow (0.02%) for 1 month. In this dosing paradigm, 26 mg/kg/day of compound A were 
administered to mice. A, Proteins from sarkosyl insoluble fractions were separated by SDS-PAGE 
and detected by total tau, pThr205, and HT7 antibodies. The sarkosyl insoluble fraction of an AD 
patient hippocampus sample (AD) was run in parallel. B, Immunoblot bands were quantified by 
densitometry. Data represent means ± S.E.M. of 9 or 10 animals. Significance is defined as * p ≤ 
0.05 (t-test) in comparison to the vehicle administered group. 
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Supplemental Figure 2. Effects of compound A on food intake and body weight of JNPL3 mouse. 
Male JNPL3 mice, age 12.5 months, were treated by feeding with chow containing 200 mg 
compound A per kg chow (0.02%) for 1 month. 
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Supplemental Figure 3. Effects of compound A on insoluble/aggregated tau in JNPL3 mouse 
brain. Male JNPL3 mice, age 12.5 months, were treated by feeding with chow containing 200 mg 
compound A per kg chow (0.02%) for 1 month. In this dosing paradigm, 26 mg/kg/day of 
compound A were administered to mice. A, Proteins were extracted by RAB-RIPA-Formic acid 
(FA) extraction procedure. Each fraction was separated by SDS-PAGE and detected by total tau 
and pThr205 antibodies. B, Immunoblot bands were quantified by densitometry. Data represent 
means ± S.E.M. of 9 or 10 animals. Significance is defined as * p ≤ 0.05 and *** p ≤ 0.001  (t-
test) in comparison to the vehicle administered group. 
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General discussion 
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In this study, I studied the potential of tau targeting strategies for AD treatment. There 
are various mechanisms related to tau toxicity, such as gene/protein expression, phosphorylation, 
degradation, and aggregation. Among these, I have focused on gene expression and 
phosphorylation, and studied details of tau gene expression modulation through transcription 
factor Sp1 and tau phosphorylation reduction by a tau kinase inhibitor. 
   In the chapter 1, I investigated modulation of tau gene expression. Though tau has an 
important role in microtubule assembly and microtubule stability for maintaining normal axonal 
integrity and neuronal function, loss of tau would not show any gross physical or behavioral 
abnormalities in the light of evidence from tau knockout mice study (4). In addition, some basic 
research indicated that reduction of tau expression is expected to exert efficacy of AD treatment. 
It was reported that Aβ induced toxicity was reduced in primary cultured neurons from tau 
knockout mice. Premature mortality and memory deficits in APP transgenic mice were prevented 
by crossing with tau knockout mice (4). Taken together, reduction of tau gene expression is an 
attractive strategy for AD treatment. 
 I investigated DNA recognition mode of Sp1 zinc finger motif in detail to obtain basic 
knowledge for tau expression modulation via Sp1. From the analysis, I found that the C-terminal 
finger induced conformation change in DNA structure of the N-terminal finger binding regions, 
and that the conformation change affected DNA recognition mode of the N-terminal finger. Sp1 
have various substrates arise from the flexible base recognition mode of N-terminal finger. 
Unique amino acid sequence of N-terminal finger in "recognition helix" comparing to other C2H2 
type zinc fingers has been considered to be one of the reasons for the flexible base recognition 
mode (93). From my research results, conformation change in DNA structure of the N-terminal 
finger would also contribute to the flexible base recognition mode of Sp1 zinc finger motif. 
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In addition to the pivotal role in tau gene expression regulation, recent growing number of 
evidences suggested the crucial roles of Sp1 in AD pathogenesis. In a pathway enrichment 
analysis on genome-wide association data from 742 Alzheimer's Disease Neuroimaging Initiative 
(ADNI) participants, Sp1 was revealed as a master regulator gene of multiple known AD-risk 
genes (94). Also, from the large-scale gene expression analysis related to aging, it is reported that 
Sp1 plays an important role in aging, which is the most common risk factor of AD (95). So 
targeting Sp1 is one of the attractive strategies for AD treatment development. It was reported 
that treatment of tolfenamic acid and mithramycin A, Sp1 inhibitors, ameliorated tau pathology, 
Aβ pathology, and cognitive impairment in AD model mice (96-98). As Sp1 interact with many 
genes, Sp1 can not only affect a number of AD related genes (e.g. APP, ApoE, BACE1, MAPT) 
but also many other genes related to transcription, tumor suppression and DNA repair (99). 
Consequently, Sp1 targeting approach has concerns of side effects as well as potential of efficacy. 
One of the possible solutions to avoid the side effects is 'Sp1 modulator', which can only affect 
the expression of essential genes for beneficial effects. There are no reports describing Sp1 and 
AD target gene(s) selective inhibitors so far, but YM155 would be a nice reference compound. It 
was reported that YM155 could selectively inhibit Sp1-survivin gene expression without 
inhibiting other Sp1 controlled gene promotors (e.g. p21, thymidine kinase) (100). In addition, as 
it was suggested that Sp1 has an important role in tau (MAPT) promoter's neuronal expression 
with undetermined cofactor(s) (8), cofactor(s) information might be a clue to find Sp1-tau 
(MAPT) selective inhibitors. To raise the possibility of success to obtain Sp1 modulator 
compounds for AD treatment, it is necessary to deeply understand the structural and biochemical 
information of Sp1-target gene interaction. My finding would be helpful for understanding basis 
for Sp1-target gene interaction, and also designing tau expression modulators via Sp1. 
93 
 
In the second chapter, I studied about tau phosphorylation reduction by GSK-3 inhibitor. The 
precise mechanism of tau toxicity remains unclear so far, tau phosphorylation has been considered 
to be a pivotal step of tau toxicity. GSK-3β is a main tau kinase and responsible for most sites of 
tau phosphorylation (101). Although compound A has inhibitory activity against CDK2/CycA 
with 10-7M order IC50 value, the influence of CDK2/CycA inhibition could be negligible owing 
to little contribution of CDK2/CycA in tau phosphorylation (101) and no CDK2/CycA expression 
in brain (102). Therefore, compound A, a potent and selective GSK-3 inhibitor, is an ideal tool to 
investigate potential of tau phosphorylation reduction thorough GSK-3 inhibition for AD 
treatment. From my study, it is indicated that tau phosphorylation reduction thorough GSK-3 
inhibition would be effective even in the later stage of pathology. This is significant finding for 
development of tau-targeting AD treatment.  
My research suggests the potential of compound A for AD treatment, but it needs to be 
confirmed whether compound A could have efficacy on cognitive deficit. Since a previous report 
has already indicated the efficacy of ATP-competitive GSK-3 inhibitor on cognitive deficit in 
preclinical studies (103), it is expected that compound A also have efficacy on cognitive deficit. 
Moreover, it is indispensable to discuss about concerns of side effects related to GSK-3 inhibition. 
GSK-3 plays crucial roles in various physiological processes via its substrates, such as 
metabolism, development, and differentiation (104). Especially, β-catenin, one of GSK-3 
substrates, is famous for its role in tumorgenesis and tumor progression (105). Most of reported 
GSK-3 inhibitors, including compound A, are ATP-competitive inhibitors, and it is theoretically 
impossible to have substrates selectivity for ATP-competitive kinase inhibitors. To avoid severe 
side effects, development of novel type of GSK-3 inhibitors, such as "substrate-competitive 
inhibitors" and "modulators", would be a great challenge for the future of AD treatment. 
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Global multi-center neuroimaging study result indicated that pathology precede clinical 
symptom in AD (2). Currently, people pay much attention to tau targeting strategy in response to 
several disappointing clinical results of Aβ targeting drugs. Much later intervention can be 
acceptable for tau targeting strategy than Aβ targeting strategy considering disease course and 
pathology establishment (106, 107). Indeed, in my study, tau targeting strategy would be effective 
in the later stage of pathology. In addition to the above mentioned approach, recent research 
progress in the tau-targeting strategy, such as anti-tau antibodies and tau antisense 
oligonucleotides, is remarkable (108, 109). It is expected that effective AD therapy will be 
developed in near future from tau targeting strategy.  
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